Celltrion will showcase its latest new drug development milestones and outline its CMO business vision at the 2026 JP Morgan Healthcare Conference, highlighting global expansion and strategic growth plans.
#YonhapInfomax #Celltrion #JPMorganHealthcareConference #NewDrugDevelopment #CMOBusiness #GlobalExpansion #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98750

South Korean brokerages have raised Celltrion's target price to 250,000 won, citing strong Q4 earnings, expanding high-margin product sales, and growth prospects from its U.S. CMO business.
#YonhapInfomax
#Celltrion #TargetPrice #Q4Earnings #HighMarginProducts #CMOBusiness
#Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=98007

Nomura maintains positive outlook on Samsung Biologics, citing potential 31% stock price increase driven by CMO growth, biosimilar sales, and U.S. Biosecurity Act benefits
#YonhapInfomax #SamsungBiologics #Nomura #CMOBusiness #Biosimilars #USBiosecurityAct #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=60169